We and others have previously demonstrated that increased expression of PKR correlates with a better prognosis in leukemia; in cancers of the lung, colon, and head and neck; and in other hematopoietic malignancies [4,10, 20]. This evidence concerns the gene EIF2AK2 and cancer.